CN107922474A - 靶向hiv融合的多肽 - Google Patents

靶向hiv融合的多肽 Download PDF

Info

Publication number
CN107922474A
CN107922474A CN201680036930.XA CN201680036930A CN107922474A CN 107922474 A CN107922474 A CN 107922474A CN 201680036930 A CN201680036930 A CN 201680036930A CN 107922474 A CN107922474 A CN 107922474A
Authority
CN
China
Prior art keywords
polypeptide
amino acid
adnectin
seq
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680036930.XA
Other languages
English (en)
Chinese (zh)
Inventor
M.R.克里斯塔尔
D.L.温塞尔
J.戴维斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ViiV Healthcare UK No 5 Ltd
Original Assignee
ViiV Healthcare UK No 5 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ViiV Healthcare UK No 5 Ltd filed Critical ViiV Healthcare UK No 5 Ltd
Publication of CN107922474A publication Critical patent/CN107922474A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Immunology (AREA)
CN201680036930.XA 2015-04-24 2016-04-14 靶向hiv融合的多肽 Pending CN107922474A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562152271P 2015-04-24 2015-04-24
US62/152271 2015-04-24
US201562257474P 2015-11-19 2015-11-19
US62/257474 2015-11-19
PCT/US2016/027424 WO2016171980A1 (fr) 2015-04-24 2016-04-14 Polypeptides ciblant une fusion du vih

Publications (1)

Publication Number Publication Date
CN107922474A true CN107922474A (zh) 2018-04-17

Family

ID=55809237

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680036930.XA Pending CN107922474A (zh) 2015-04-24 2016-04-14 靶向hiv融合的多肽

Country Status (25)

Country Link
US (2) US10407490B2 (fr)
EP (2) EP3985020A1 (fr)
JP (3) JP6894846B2 (fr)
KR (1) KR20170138558A (fr)
CN (1) CN107922474A (fr)
AU (2) AU2016252008B2 (fr)
BR (1) BR112017022790A2 (fr)
CA (1) CA2983276A1 (fr)
CL (1) CL2017002687A1 (fr)
CO (1) CO2017011583A2 (fr)
CR (1) CR20170482A (fr)
DO (1) DOP2017000246A (fr)
EA (1) EA035332B1 (fr)
ES (1) ES2884267T3 (fr)
HK (1) HK1243432A1 (fr)
IL (1) IL255122A0 (fr)
MA (2) MA41943A (fr)
MX (1) MX2017013687A (fr)
PE (1) PE20180162A1 (fr)
PH (1) PH12017501914A1 (fr)
PT (1) PT3286212T (fr)
SG (1) SG11201708441RA (fr)
TW (1) TW201643185A (fr)
UY (1) UY36650A (fr)
WO (1) WO2016171980A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114605505A (zh) * 2018-08-09 2022-06-10 东莞市朋志生物科技有限公司 用于检测hiv-1的合成肽
WO2023030312A1 (fr) * 2021-08-30 2023-03-09 康霖生物科技（杭州）有限公司 Construction de séquence génique pour la thérapie génique contre l'infection par le vih

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106755100A (zh) * 2017-02-20 2017-05-31 李因传 可控性hiv‑1基因组靶向编辑系统和其靶向载运系统
EP3728310A1 (fr) 2017-12-18 2020-10-28 VIIV Healthcare UK (No.5) Limited Polypeptides de liaison à un antigène
WO2021081515A2 (fr) * 2019-10-25 2021-04-29 Cidara Therapeutics, Inc. Compositions et procédés pour le traitement du virus de l'immunodéficience humaine

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1685064A (zh) * 2002-09-27 2005-10-19 唐纳士公司 用于预防和治疗获得性免疫缺陷综合症的协同组合物
WO2011077093A1 (fr) * 2009-12-22 2011-06-30 Aarhus Universitet Molécules bivalentes destinées à inhiber l'entrée du vih

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US5672502A (en) 1985-06-28 1997-09-30 Celltech Therapeutics Limited Animal cell culture
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
US6048728A (en) 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
JP3051145B2 (ja) 1990-08-28 2000-06-12 住友製薬株式会社 新規なポリエチレングリコール誘導体修飾ペプチド
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
ATE196606T1 (de) 1992-11-13 2000-10-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörpern, die gegen ein differenzierung-antigen gerichtet sind, dessen expression auf menschliche b lymphozyt beschränkt ist, für die behandlung von b-zell-lymphoma
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US6261804B1 (en) 1997-01-21 2001-07-17 The General Hospital Corporation Selection of proteins using RNA-protein fusions
WO1998031700A1 (fr) 1997-01-21 1998-07-23 The General Hospital Corporation Selection de proteines a l'aide de fusions arn-proteine
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
AU2265701A (en) * 1999-12-16 2001-06-25 Tanox, Inc. Anti-hiv-1 conjugates for treatment of hiv disease
US20050287153A1 (en) 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
JP4578768B2 (ja) 2000-07-11 2010-11-10 リサーチ コーポレイション テクノロジーズ，インコーポレイテッド 人工抗体ポリペプチド
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
ES2551682T3 (es) 2002-11-08 2015-11-23 Ablynx N.V. Anticuerpos de dominio simple dirigidos contra factor de necrosis tumoral-alfa y usos para los mismos
EP1729795B1 (fr) 2004-02-09 2016-02-03 Human Genome Sciences, Inc. Proteines hybrides d'albumine
US20070269422A1 (en) 2006-05-17 2007-11-22 Ablynx N.V. Serum albumin binding proteins with long half-lives
AR067584A1 (es) * 2007-07-20 2009-10-14 Hoffmann La Roche Un conjugado de un anticuerpo contra la cd4 y peptidos antifusogenicos
BRPI0821924A2 (pt) 2007-12-27 2015-07-07 Novartis Ag Moléculas de ligação baseadas em fibronectina melhoradas e seu uso
EP2274331B1 (fr) 2008-05-02 2013-11-06 Novartis AG Molécules de liaison à base de fibronectine améliorées et leurs utilisations
US8278419B2 (en) * 2008-10-31 2012-10-02 Centocor Ortho Biotech Inc. Fibronectin type III domain based scaffold compositions, methods and uses
GB0920944D0 (en) * 2009-11-30 2010-01-13 Biotest Ag Agents for treating disease
BR112012026216B1 (pt) * 2010-04-13 2022-07-26 Bristol-Myers Squibb Company Proteínas com domínio "scaffold" baseado em fibronectina que se ligam à pcsk9, seu uso, bem como composição farmacêutica compreendendo as mesmas
TW201138808A (en) * 2010-05-03 2011-11-16 Bristol Myers Squibb Co Serum albumin binding molecules
JP6145404B2 (ja) * 2010-05-07 2017-06-14 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト エクスビボでの細胞の検出のための診断的方法
US9260496B2 (en) * 2010-12-22 2016-02-16 Bristol-Myers Squibb Company Fibronectin based scaffold domain proteins that bind IL-23
EP2714971A4 (fr) * 2011-05-23 2015-01-21 Phylogica Ltd Procédé de détermination, d'identification ou d'isolement de peptides pénétrant dans des cellules
EP4151785A1 (fr) * 2011-09-27 2023-03-22 Janssen Biotech, Inc. Échafaudage de protéine à base de répétition de fibronectine de type iii avec des surfaces de liaison alternatives
US20150361159A1 (en) * 2013-02-01 2015-12-17 Bristol-Myers Squibb Company Fibronectin based scaffold proteins
US20160152686A1 (en) * 2013-03-13 2016-06-02 Bristol-Myers Squibb Company Fibronectin based scaffold domains linked to serum albumin or moiety binding thereto
CN103333255A (zh) 2013-06-28 2013-10-02 复旦大学 一种长效hiv‐1膜融合抑制剂

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1685064A (zh) * 2002-09-27 2005-10-19 唐纳士公司 用于预防和治疗获得性免疫缺陷综合症的协同组合物
WO2011077093A1 (fr) * 2009-12-22 2011-06-30 Aarhus Universitet Molécules bivalentes destinées à inhiber l'entrée du vih

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LAI WEI-HONG 等: "HIV entry inhibitors:progress in development and application", 《ACTA PHARMACEUTICA SINICA》 *
张沙 等: "胆固醇修饰的非天然HR序列肽类HIV-1融合抑制剂的合成及活性初筛", 《高等学校化学学报》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114605505A (zh) * 2018-08-09 2022-06-10 东莞市朋志生物科技有限公司 用于检测hiv-1的合成肽
CN114605505B (zh) * 2018-08-09 2023-01-31 东莞市朋志生物科技有限公司 用于检测hiv-1的合成肽
WO2023030312A1 (fr) * 2021-08-30 2023-03-09 康霖生物科技（杭州）有限公司 Construction de séquence génique pour la thérapie génique contre l'infection par le vih

Also Published As

Publication number Publication date
US20190359688A1 (en) 2019-11-28
JP2023055875A (ja) 2023-04-18
US20180111980A1 (en) 2018-04-26
JP7465378B2 (ja) 2024-04-10
ES2884267T3 (es) 2021-12-10
CA2983276A1 (fr) 2016-10-27
IL255122A0 (en) 2017-12-31
EP3985020A1 (fr) 2022-04-20
MX2017013687A (es) 2018-07-06
US10407490B2 (en) 2019-09-10
JP2018516247A (ja) 2018-06-21
AU2019226255A1 (en) 2019-09-26
BR112017022790A2 (pt) 2018-07-17
EA201792269A1 (ru) 2018-04-30
JP6894846B2 (ja) 2021-06-30
AU2016252008A1 (en) 2017-11-09
CO2017011583A2 (es) 2018-04-19
CL2017002687A1 (es) 2018-04-20
SG11201708441RA (en) 2017-11-29
MA56222A (fr) 2022-04-20
PE20180162A1 (es) 2018-01-18
CR20170482A (es) 2018-03-07
WO2016171980A1 (fr) 2016-10-27
DOP2017000246A (es) 2018-01-31
UY36650A (es) 2016-11-30
TW201643185A (zh) 2016-12-16
MA41943A (fr) 2018-02-28
PH12017501914A1 (en) 2018-03-05
HK1243432A1 (zh) 2018-07-13
JP2021035951A (ja) 2021-03-04
EP3286212A1 (fr) 2018-02-28
US11155602B2 (en) 2021-10-26
EP3286212B1 (fr) 2021-06-02
AU2016252008B2 (en) 2019-06-13
EA035332B1 (ru) 2020-05-28
KR20170138558A (ko) 2017-12-15
PT3286212T (pt) 2021-08-24

Similar Documents

Publication Publication Date Title
JP7465378B2 (ja) Ｈｉｖ融合体を標的とするポリペプチド
TWI694085B (zh) 結合至肌肉生長抑制素（ｍｙｏｓｔａｔｉｎ）以纖維連接蛋白爲主之支架結構域蛋白質
CN102781960B (zh) Hsa相关组合物及使用方法
CN104918632B (zh) 治疗糖尿病或糖胖病的包括胃泌酸调节素类似物的组合物
CN106604739A (zh) 包括胰岛素和glp‑1/胰高血糖素双重激动剂的用于治疗糖尿病的组合物
CN102099373A (zh) 基于纤连蛋白的多价支架结构域蛋白
CN106795213A (zh) 选择性地活化调节性t细胞用于治疗自身免疫病的分子
CN104271588A (zh) 具有增强的作用持续时间和降低的免疫原性的工程改造的多肽
WO2014165093A2 (fr) Domaines d'échafaudage à base de fibronectine liés à une sérum albumine ou fragment se liant à celle-ci
CN101965198A (zh) 改进的基于纤连蛋白的结合分子及其用途
CN103379915A (zh) Hsa相关组合物及使用方法
CN105916877A (zh) 长效胰岛素及其用途
IL293680A (en) il-2 orthologs and methods of use
EP2992021A2 (fr) Nouveau procédé de clonage, d'expression et de purification pour la préparation de ranibizumab
CN102875683A (zh) 长效重组人生长激素的Fc融合蛋白
CN108727486A (zh) 长效神经生长因子、制备方法及其组合物
IL293822A (en) Cd122 with weird icd stat signal
CN110536899A (zh) 对胰岛素受体具有降低的亲和力的胰岛素类似物复合物及其用途
US20220267434A1 (en) Long-Acting Therapeutic Fusion Proteins
CN101142234A (zh) 结合红细胞生成素受体的新肽
JP2021507717A (ja) 抗原結合性ポリペプチド
CN101636410A (zh) 基于酪氨酸激酶受体（包括igf-ir）的工程化蛋白质的靶向治疗剂

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180417

WD01 Invention patent application deemed withdrawn after publication